论文部分内容阅读
目的比较含吡柔比星(THP)和阿霉素(ADM)的方案治疗多发性骨髓瘤(MM)的疗效和毒性反应。方法65例MM患者分别接受VTD和VAD方案治疗,每28d为一疗程,治疗3～4个疗程。结果THP组和ADM组的有效率分别为71.43%和64.86%,二者之间无统计学差异(P>0.05);两组的血液学毒性及胃肠道反应均无差异(P>0.05),THP组心脏毒性发生率3.57%,脱发发生率14.29%,均明显低于ADM组的29.73%和51.35%(P<0.01);THP组肝肾功能损伤发生率3.57%,也明显低于ADM组的21.62%(P<0.05)。结论THP与ADM相比,疗效略高,且心脏毒性、脱发和肝肾功能损伤等反应明显降低,更适合MM患者,值得推广应用。
Objective To compare the efficacy and toxicity of multiple myeloma (MM) regimens with pirarubicin (THP) and doxorubicin (ADM) regimens. Methods Sixty-five patients with MM were treated with VTD and VAD regimen respectively. Each treatment consisted of one course of 28 days and three to four courses of treatment. Results The effective rates of THP group and ADM group were 71.43% and 64.86% respectively, there was no significant difference between the two groups (P> 0.05). There was no difference between the two groups in hematological toxicity and gastrointestinal reaction (P> 0.05) , The incidence of cardiotoxicity in THP group was 3.57%, the incidence of hair loss was 14.29%, which were significantly lower than those in ADM group (29.73% vs 51.35%, P <0.01). The incidence of hepatic and renal dysfunction in THP group was 3.57% 21.62% of the group (P <0.05). Conclusions Compared with ADM, THP has a slightly higher therapeutic effect, and its cardiotoxicity, hair loss, liver and kidney function and other reactions are significantly reduced. It is more suitable for MM patients and is worthy of promotion and application.